Biolectron Sold to Biomet.

Business Editors

ALLENDALE, N.J.--(BUSINESS WIRE)--Sept. 25, 2000

Biolectron, Inc has announced today that it has entered into a definitive agreement to be acquired by Biomet Inc.'s, (NASDAQ:BMET) EBI subsidiary for $90 million in cash.

The transaction is expected to close by end of business today. Biolectron, a member of the Chen Family group of companies, was founded in 1977 to develop and commercialize products addressing the spinal fusion, fracture healing and arthroscopy market segments.

Kimball C. Chen, Chairman of Biolectron, said, "I and the other shareholders of Biolectron are proud to pass our Company into the capable hands of Biomet whose broader resources and focused management will be able to bring more effectively the benefits of Biolectron research and development to patients of global markets."

Gary Grenter, President and Chief Executive Officer of Biolectron, said, "I have had the exciting responsibility of leading Biolectron through its recent period of industry leading growth and I am confident that under Biomet's management the exceptional efficacy of Biolectron's technologies and products will increasingly be recognized by doctors, patients and reimbursers."

Biolectron's non-invasive spinal stimulator, SpinalPak, was approved through PMA supplement in September, 1999 as a proprietary capacitive coupling product for use in the post-operative treatment of spinal fusion surgery. With SpinalPak offered in conjunction with EBI's implant spinal fusion stimulation product, the SpF system EBI will now be able to offer its customers the leading technologies for either inpatient or outpatient settings. Biolectron's OrthoPak which was approved by the FDA in 1986, is a small lightweight bone growth stimulator product which is used in connection with treating non-union fractures. EBI's acquisition of the OrthoPak complements their range of products for bone growth stimulation markets.

Biolectron also manufactures and markets CurvTek, a proprietary instrument for use in the re-attachment of soft tissue to bone. The CurvTek product received clearance for the FDA in 1997 and will augment the product portfolio of Biomet's Arthrotek arthroscopy subsidiary.

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy, including fixation devices, electrical bone growth stimulators, general surgical instruments, arthroscopy products, spinal implants, bone cements, bone substitutes, craniomaxillofacial implants and dental implants. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.

For further information, contact Jay Penchina, Biolectron's Vice President and CFO, at [phone].